UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 14, 2015
OMEROS CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Washington |
|
001-34475 |
|
91-1663741 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
201 Elliott Avenue West
Seattle, Washington 98119
(Address of principal executive offices, including zip code)
(206) 676-5000
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(d) On June 14, 2015, the board of directors of Omeros Corporation, or Omeros, upon recommendation from the nominating and governance
committee of Omeros board of directors, appointed Rajiv Shah, M.D., 42, as a director of Omeros, effective immediately. Dr. Shah was appointed as a Class I director with a term expiring at Omeros 2016 annual meeting of shareholders.
Dr. Shah is currently a Distinguished Fellow at Georgetown Universitys School of Foreign Service. In connection with Dr. Shahs appointment, the board of directors designated him as an independent director under Nasdaq listing
standards. Dr. Shahs initial committee assignment will be determined at a later date.
Dr. Shah will receive compensation
and be subject to indemnification for serving as a member of the board of directors consistent with Omeros normal arrangements for non-employee directors, which were described in the proxy statement for Omeros 2015 annual meeting of
shareholders. Pursuant to the non-employee director compensation policy, on the date of his appointment Dr. Shah was granted a stock option to purchase 15,000 shares of Omeros common stock.
As of the date of this Current Report on Form 8-K, neither Dr. Shah nor any of his immediate family members is a party, either directly
or indirectly, to any transaction that would be required to be reported under Rule 404(a) of Regulation S-K, nor is Dr. Shah party to any understanding or arrangement pursuant to which he was appointed as a director.
On June 17, 2015, Omeros issued a press release announcing Dr. Shahs appointment to the board of directors of Omeros. A copy
of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit Number |
|
Exhibit Description |
|
|
99.1 |
|
Press Release, dated June 17, 2015, announcing appointment of Rajiv Shah, M.D., to the Board of Directors of Omeros Corporation. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
OMEROS CORPORATION |
|
|
By: |
|
/s/ Gregory A. Demopulos |
|
|
Gregory A. Demopulos, M.D. |
|
|
President, Chief Executive Officer and |
|
|
Chairman of the Board of Directors |
Date: June 17, 2015
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release dated June 17, 2015, announcing appointment of Rajiv Shah, M.D., to the Board of Directors of Omeros Corporation. |
Exhibit 99.1
Rajiv Shah, M.D., Appointed to Omeros Board of Directors
SEATTLE, WA June 17, 2015 Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the
United States Agency for International Development (USAID), has been appointed to serve on the companys board of directors.
From 2010 to 2015,
Dr. Shah served as Administrator of USAID, the U.S. government agency responsible for administering civilian foreign aid. During his tenure, Dr. Shah led the efforts of nearly 10,000 staff in more than 70 countries around the world to
advance USAIDs mission of ending extreme poverty and promoting resilient, democratic societies.
We are pleased to welcome Raj to our board
he brings an outstanding scientific background together with a proven track record of innovation in leading the worlds premier development organization, stated Gregory A. Demopulos, M.D., chairman and chief executive officer of
Omeros. While at USAID, Raj creatively forged strategic partnerships with corporations and private capital to address some of the most pressing global problems, and he is a valuable addition to our team as we continue to expand our development
and commercial activities.
From 2009 to 2010, Dr. Shah served as the Under Secretary for Research, Education and Economics and Chief Scientist
at the U.S. Department of Agriculture. Prior to his service in the Obama Administration, he worked in senior roles at the Bill & Melinda Gates Foundation, leading the Foundations efforts in global health, agriculture, and financial
services. He also played a key role in the Foundations efforts to advance domestic health care reform.
I am honored to join the Omeros
board, said Dr. Shah. With its strong leadership, Omeros is executing on its integrated strategy of commercial success with Omidria® to advance its deep and exciting pipeline
of clinical and preclinical small-molecule and protein therapeutic programs. The strength of science and translational capabilities at Omeros are impressive, and I look forward to contributing to the future growth and direction of the company.
Dr. Shah is currently a Distinguished Fellow at Georgetown Universitys School of Foreign Service, where his work focuses on international
development and building out Georgetowns masters program in Global Human Development. He also sits on the board of directors of Arcadia Biosciences, Inc. and the board of trustees of the Rockefeller Foundation. Dr. Shah earned his
M.D. from the University of Pennsylvania Medical School, his Master of Science in health economics at the Wharton School of Business and his Bachelor of Science in economics from the University of Michigan.
About Omeros Corporation
Omeros is a biopharmaceutical
company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived
from its proprietary PharmacoSurgery® platform, the companys first drug product, Omidria® (phenylephrine and ketorolac
injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain. The marketing authorization application (MAA) for Omidria recently received a unanimous positive opinion from the European Medicines Agency, which forwarded the MAA to the European Commission
for decision regarding final approval. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntingtons disease, schizophrenia, and cognitive impairment; addictive and compulsive
disorders; and preventing problems associated with surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical
industry for drug development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by
terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential,
predict, project, should, will, would and similar expressions. Forward-looking statements are based on managements beliefs and assumptions and on information available to management
only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros ability to
obtain regulatory approval for its Marketing Authorization Application in the EU for the commercialization of Omidria®, Omeros unproven preclinical and clinical development activities,
regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading Risk Factors in the companys Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2015. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no
obligation to update these forward-looking statements, even if new information becomes available in the future.
Contact:
Omeros Corporation
Investor Relations
206.676.5000
ir@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024